Competitor Analysis: PTH Receptor Agonists, Teriparatide Biosimilars and Biosuperiors
Product description
Parathyroid hormone/parathyroid hormone-related peptide receptor also known as parathyroid hormone 1 receptor (PTH1R) functions as a receptor for parathyroid hormone (PTH) and for parathyroid hormone-related protein (PTHrP). FORTEO (teriparatide) is recombinant human parathyroid hormone analog (1-34), marketed since 2002 for the treatment of osteoporosis and related indications where an increase of bone mass is desirable. With 2012 sales of over US$ 1 bln and the forthcoming patent expiry, teriparatide is an attractive target for biosimilar developments as well as for next generation improved PTH receptor agonist products.
The present Competitive Intelligence report about PTH Receptor Agonists, Teriparatide Biosimilars and Biosuperiors provides a competitor evaluation in the field of protein- and peptide-based agonists of the parathyroid hormone (PTH) receptor for the treatment of osteoporosis as of October 2013. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
The report includes a compilation of currently active projects in research and development of proteins and peptides as agonists of the parathyroid hormone (PTH) receptor. In addition, the report lists company-specific R&D pipelines of PTH receptor agonists. Competitor projects are listed in a tabular format providing information on:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
Parathyroid hormone/parathyroid hormone-related peptide receptor also known as parathyroid hormone 1 receptor (PTH1R) functions as a receptor for parathyroid hormone (PTH) and for parathyroid hormone-related protein (PTHrP). FORTEO (teriparatide) is recombinant human parathyroid hormone analog (1-34), marketed since 2002 for the treatment of osteoporosis and related indications where an increase of bone mass is desirable. With 2012 sales of over US$ 1 bln and the forthcoming patent expiry, teriparatide is an attractive target for biosimilar developments as well as for next generation improved PTH receptor agonist products.
The present Competitive Intelligence report about PTH Receptor Agonists, Teriparatide Biosimilars and Biosuperiors provides a competitor evaluation in the field of protein- and peptide-based agonists of the parathyroid hormone (PTH) receptor for the treatment of osteoporosis as of October 2013. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
The report includes a compilation of currently active projects in research and development of proteins and peptides as agonists of the parathyroid hormone (PTH) receptor. In addition, the report lists company-specific R&D pipelines of PTH receptor agonists. Competitor projects are listed in a tabular format providing information on:
- Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Company,
- Product Category,
- Indication,
- R&D Stage
- additional comments with a hyperlink leading to the source of information.
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
- 1st Generation PTH Receptor Agonists
- Teriparatide Biosimilars
- PTH-related Proteins/Peptides
- PTH Variants
- Nasal Drug Delivery Solutions for rhPTH Receptor Agonists
- Oral Drug Delivery Solutions for rhPTH Receptor Agonists
- Transdermal Drug Delivery Solutions for rhPTH Receptor Agonists
- Corporate PTH Receptor Agonist R&D Pipelines
